Medicines such as GLP-1 receptor agonists can help people with type 2 diabetes lose substantial amounts of weight, but doctors have questioned what that weight loss might mean for aging bones.
A large UCLA Health study now offers some reassuring evidence. Instead of seeing more serious fractures, researchers found fewer among patients who started GLP-1 treatment.
The study examined health records from almost 134,000 Americans between ages 50 and 90 who had type 2 diabetes. Over three years, people beginning GLP-1 medicines were less likely to suffer fragility fractures than similar patients beginning DPP-4 inhibitors. The difference in risk was about 21%.
A fragility fracture is a broken bone that happens after a relatively small amount of force. A typical example is breaking a hip after falling from a standing position. Doctors often consider these fractures a warning that bones may have become weaker than they should be.
Older adults are particularly vulnerable to the consequences. A broken hip or thigh bone can suddenly turn an independent person into someone who needs surgery, rehabilitation, and help with everyday activities. Spinal fractures can also cause lasting pain, reduced movement, and changes in posture.
People with type 2 diabetes have a complicated relationship with bone health. Some may have bone density measurements that do not appear extremely low, yet their fracture risk can still be higher than expected. Diabetes can affect bone quality, balance, vision, nerves, muscles, and other factors that influence the chance of falling or breaking a bone.
Obesity can add another layer of complexity. Carrying extra weight places greater loads on the skeleton, while losing a large amount of weight can sometimes reduce bone and muscle mass. Because GLP-1 medicines can cause major weight loss, researchers have wanted to know whether their benefits come with an increased fracture risk.
GLP-1 receptor agonists were originally developed mainly to treat type 2 diabetes. They work by copying signals from a hormone involved in controlling blood sugar and appetite. These medicines can help the body release insulin when needed, slow digestion, reduce hunger, and support weight loss.
Their use has expanded rapidly, making questions about long-term safety increasingly important. Even a relatively small change in fracture risk could matter when millions of people use a medicine. Yet fractures happen much less often than everyday side effects, so researchers need very large groups of patients to study them properly.
Dr. Christopher Hamad and colleagues at UCLA Health addressed this problem using electronic health records. They identified adults with type 2 diabetes who were new users of GLP-1 receptor agonists and compared them with new users of DPP-4 inhibitors. DPP-4 drugs also treat type 2 diabetes but work differently and generally have much smaller effects on body weight.
Over the three-year study period, the GLP-1 group had a 21% lower risk of fragility fractures. The most notable reductions involved the hip, femur, and spine. These are among the fracture sites that can have the greatest effect on mobility and independence.
The researchers also performed an additional comparison involving people without diabetes. The lower fracture risk was associated only with participants who had type 2 diabetes compared with a matched group without diabetes. That finding raises interesting questions about whether the apparent benefit is related specifically to the biology of diabetes.
One possibility is that improved control of diabetes has effects that indirectly protect bones. Another is that GLP-1 medicines could influence processes related to inflammation, bone turnover, muscles, or body composition. Changes in weight and mobility could also affect the likelihood or impact of falls.
At this stage, however, scientists do not know the explanation. The new research was designed to find an association in medical records, not to reveal the biological mechanism behind it. Understanding why the fracture rate differed will require additional studies.
The research was published in JAMA Network Open. Dr. Hamad noted that earlier studies often had too few participants or were not specifically designed to answer the fracture question. Access to records from more than 133,000 patients made it possible to examine a relatively uncommon outcome with greater statistical power.
The size of the study is a major advantage, but size alone cannot turn an observational study into proof. Researchers did not randomly decide which patients received GLP-1 drugs and which received DPP-4 inhibitors. Doctors and patients made those treatment choices in normal clinical practice.
This means the groups could have differed in important ways before treatment began. Differences in health, weight, exercise, fall risk, other medications, socioeconomic factors, or medical monitoring could potentially influence the results. Statistical methods can reduce these differences but cannot always remove them completely.
The three-year follow-up is another consideration. Bone changes may develop slowly, and many patients could remain on GLP-1 medicines for longer than the study period. Long-term research will be needed to understand what happens to bone strength and fracture risk after extended use.
Researchers also need studies that directly measure bone health rather than relying mainly on diagnoses recorded in health systems. Measurements of bone density, bone structure, muscle mass, nutrition, and physical function could reveal whether GLP-1 medicines change the skeleton itself. Tracking falls would also help separate effects on bone strength from effects on balance or mobility.
The findings should therefore not be interpreted as proof that GLP-1 medicines are fracture-prevention drugs. Their established roles remain treatment of diabetes and, for certain products and patients, obesity and related health risks. Whether fracture protection becomes a recognized additional benefit will depend on stronger evidence.
Even so, the results address an important safety concern. Rapid weight loss can raise questions about loss of lean tissue and bone, particularly among older adults. Finding a lower rather than higher fracture rate in this very large diabetes population suggests the relationship is more complicated than simply assuming that weight loss weakens bones.
For people with type 2 diabetes, protecting bones still requires a broad approach. Adequate nutrition, appropriate physical activity, maintaining muscle strength, preventing falls, and treating osteoporosis when needed remain important. Medication choices should be made with a health professional based on the person’s overall risks and benefits.
The study adds an intriguing new piece to the rapidly growing research on GLP-1 medicines. Its strongest contribution is the large real-world patient population and the clear difference observed between two diabetes treatments, while its biggest limitation is that it cannot establish cause and effect.
If future controlled and biological studies confirm the result, fewer serious fractures could turn out to be an unexpected additional benefit of GLP-1 treatment for some people with type 2 diabetes.
If you care about health, please read studies that plant-based diets can harm your bone health without these nutrients, and how to ease arthritis with anti-inflammatory foods.
For more health information, please see recent studies that too much of this vitamin may increase your risk of bone fractures, and results showing this type of exercise may protect your bone health, slow down bone aging.
Source: UCLA Health.
